AUTHORS
Snigdha Nagabhyrava, Stephanie Lobaugh2, Parastoo B. Dahi, MD3, Sigrun Einarsdottir, MD, PhD4, Silvia Escribano Serrat, MD5, Marina Gomez-Llobell, MD, MSc6, Lorenzo Falchi, MD7, Richard J. Lin, MD, PhD8, Jennifer Kimberly Lue, M.D.9, Maria Lia Palomba, MD10, Jae H Park, MD11, Miguel-Angel Perales, MD12, Gilles Salles I, MD, PhD13, Craig Sauter, MD14, Michael Scordo, MD15, Gunjan L. Shah, MD, MS16, Roni Shouval Jr, MD, PhD17, Ying Liu, MD18, Sarah Samorodnitsky, PhD19, Wenbin Xiao, MD, PhD20, Alexander P. Boardman, MD21
AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Background
Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of relapsed/refractory lymphomas, yet toxicities including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and immune effector cell-associated hematotoxicity (ICAHT) remain significant barriers. Mutations associated with clonal hematopoiesis (CH) are frequently identified in patients prior to CAR-T therapy, but the impact on CAR-T outcomes and toxicities in lymphoma patients is understudied.
Methods
This is a single-center, retrospective study of patients at Memorial Sloan Kettering Cancer Center (MSK) who received CAR-T therapy for diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), or chronic lymphocytic leukemia (CLL) between 2017 and 2026. Patients who underwent targeted next generation sequencing (MSK IMPACT: Integrated Mutation Profiling for Actionable Cancer Targets; Ptashkin et al, Nat Comm, 2023) on either peripheral blood or bone marrow sample prior to CAR T cell infusion were included. Somatic driver mutations present at variant allele fractions (VAF) >= 0.02 were reviewed and adjudicated by a board-certified hematologist and a hematopathologist to classify cases as CH-positive or CH-negative. Survival outcomes were analyzed from the date of infusion. CRS and ICANS were graded according to ASTCT criteria, and ICAHT by EHA/EBMT criteria. OS and PFS were estimated using the Kaplan-Meier method, and log-rank tests were used to compare groups. Cox Proportional Hazards regression was used to examine associations with OS and PFS. Gray’s test was used to test for a difference in cumulative incidence of late ICAHT. Fisher’s exact tests were used to test for differences in best overall response rate (ORR), complete response rate (CRR), and toxicities. Median follow-up was calculated using the reverse Kaplan-Meier method.
Results
We screened 610 lymphoma patients who received CD19 CAR-T cell therapy at MSKCC. Among 93 patients with available bone marrow (n=75) or peripheral blood (n=18) sequencing data, 15 (16%) were characterized as CH-positive and 78 (84%) were CH-negative. Among CH-positive patients, DNMT3A (53%) was the most frequently mutated gene, followed by TET2 (13%), TP53 (13%) and PHIP (13%). The median VAF was 6.5 (IQR 3.5-33%). Twelve patients (80%) had a single CH-mutation, two patients (13%) had two mutated genes, and one patient (7%) had three mutated genes.
Age, sex, KPS(>=90 vs <90), and bridging therapy were well matched between groups. Though not significant, CLL (13% vs 4%) and FL (13% vs 6%) were numerically more frequent in CH-positive patients, whereas MCL was numerically more common in the CH-negative group (27% vs 13%) (overall p=0.2). CD19 CAR-T cell products differed numerically between groups with CH-positive patients receiving axi-cel (7% vs 23%) and tecartus (0% vs 14%) less commonly, and liso-cel (73% vs 51%) and tisa-cel (20% vs 12%) more frequently (overall p=0.14).
Best ORR and CRR at Day 100 after CAR-T cell infusion were similar between groups. At a median follow up time of 30 months, PFS was more favorable in the CH-positive group (median PFS (95% CI): NR (NR - NR) versus 6 (5 – 10) months, log-rank p = 0.015). The two-year PFS for each group was 75% and 27%, respectively. Using multivariable Cox proportional hazards regression for PFS adjusting for age and diagnosis, CH status remained significant (HR 0.26 (0.08 - 0.85); p = 0.026). OS was not significantly different between groups. Grade 2+ CRS occurred less frequently in CH-positive patients (7% vs 38%, p= 0.03). We did not observe significant differences in overall incidence of CRS, ICANS, or early neutropenic ICAHT (n-ICAHT), nor in cumulative incidence late n-ICAHT.
Conclusions
Among a cohort of lymphoma patients treated with CD19 CAR-T with available marrow or peripheral blood targeted exome sequencing, CH was present in 16% (15/93). Though the small number of CH-positive patients precludes definitive conclusions, CH was associated with longer PFS after adjusting for age and disease. Grade 2+ CRS was less frequent in CH-positive patients while other disease and toxicity outcomes, including hematologic toxicity did not differ significantly. These findings contrast with prior reports in myeloma and lymphoma patients with CH, and larger multicenter cohorts are needed to confirm these findings.
DISCLOSURES
Snigdha Nagabhyrava: No relevant conflicts of interest to declare.